Ribozyme Pharmaceuticals, Incorporated

Sirna Therapeutics, Inc.

Alex B Burgin

Leonid Beigelman

Jasenka Matulic-Adamic

Alexander Karpeisky

David Sweedler

Amber Beaudry

Shawn Patrick Zinnen

Laurent Bellon

Nassim Usman

Alex Karpeisky

Novel nucleotide triphosphates, methods of synthesis and process of incorporating these nucleotide triphosphates into oligonucleotides, and isolation of novel nucleic acid catalysts (e.g., ribozymes) are disclosed. Also, described are the use of novel enzymatic nucleic acid molecules to inhibit HER2/neu/ErbB2 gene expression and their applications in human therapy.

Oligoribonucleotides with enzymatic activity

Nucleic acid catalysts, method of screening for variants of nucleic acid catalysts, synthesis of ribozyme libraries and discovery of gene sequences are described.

Method for screening nucleic acid catalysts

Synthetic ribonucleic acids with RNAse activity

Novel nucleoside triphosphates, methods of synthesis and process of incorporating these nucleoside triphosphates into oligonucleotides are disclosed.

Nucleoside triphosphates and their incorporation into oligonucleotides

Novel nucleotide triphosphates, methods of synthesis and process of incorporating these nucleotide triphosphates into oligonucleotides, and isolation of novel nucleic acid catalysts (e.g., ribozymes) are disclosed.

An enzymatic nucleic acid having a modification selected from pyridin-4-one, pyridin-2-one, phenyl, pseudouracil, 2, 4, 6-trimethoxy benzene, 3-methyluracil, dihydrouracil, naphthyl, 6-methyl-uracil and aminophenyl.

Growing community of inventors

Chula Vista, CA, United States of America

Alex B Burgin